![]() Data generated with PSPP positive and negative controls can be found by visiting the Database tab, with more data to be added as it is collected. On that page, you can also find descriptions of the models and endpoints used to assess assets in the program. You can visit the Models tab of the PSPP website to learn more about the PSPP workflow used to guide the testing of assets through a sequence of assays. Armed with an easy-to-use GUI, JASP allows both classical and Bayesian analyses. JASP is an open-source statistics program that is free, friendly, and flexible. For more details on the scientific advisory board, click here. The PSPP website aims to provide public access to our screening workflow, testing protocols, and non-confidential data. Henrik Singmann, University College London. Screening personnel are blinded to both the structure and the source of submitted compounds, and the PSPP provides screening results exclusively to the asset owner. This webpage allows you to use PSPP to read SPSS or SPSS/PC+ system files (. ![]() To further ensure confidentiality and blinding, the PSPP assigns each newly submitted compound a unique number code to be used in communications, tracking, and analysis. PSPP evaluation of an asset is agreed upon by participants in collaboration with PSPP personnel. Chemical structures are considered proprietary unless otherwise specified by the participant. All screening and other communication activities are performed in strict confidence. The participant agreement defines the legal parameters for the partnership and protects the participant’s IP. ![]() A signed participant agreement is required for consideration of entry into the program. NINDS recognizes the importance of confidentiality to the success of the PSPP and its participants. A one-page summary of the PSPP can be found here. The program offers testing including an assessment of in vitro and pharmacokinetic profiles, side effect profiles, abuse liability, and efficacy in models relevant to human pain conditions. The PSPP is an efficient, rigorous, one-stop screening resource to accelerate discovery of effective, non-addictive, non-opioid pain therapies. In response, the National Institute of Neurological Disorders and Stroke (NINDS) created the Preclinical Screening Platform for Pain (PSPP) to identify and profile non-addictive therapeutics for pain. This critical need aligns with the Helping to End Addiction Long-term SM Initiative, or NIH HEAL Initiative, goal to accelerate the discovery and preclinical development of non-addictive pain treatments for the more than 25 million Americans who live with daily chronic pain and rely on opioid medications for pain management. The Federal Pain Research Strategy identified an urgent need to reduce reliance on prescription opioid medications through the development of new, non-opioid pharmacologic and non-pharmacologic treatments for pain.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |